SCHEMBL4490983

SCHEMBL4490983

Cc1[nH]c(C)c(-c2c[nH]c(-c3ccccc3F)cc2=O)c(=O)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
NPC1 O15118 1/20 0.36
MTOR P42345 1/20 0.36
PTGS2 P35354 1/20 0.34
CDC7 O00311 1/20 0.33
HSP90AA1 P07900 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
CASP3 P42574 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
PIM1 P11309 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473579 0.88 PIM1 (0.41) TNKS2PTGS2HSP90AA1POLBHPGD
SCHEMBL4486516 0.86 ADORA2A (0.41) ADORA2AADORA1TNKSTNKS2NPC1
SCHEMBL4564904 0.85 HSD11B1 (0.35) HPGDKMT2AGAANPY5R
SCHEMBL4485647 0.83 HSD11B1 (0.35) MAPTHPGDKMT2ALMNA
SCHEMBL4486317 0.83 MAPT (0.35) MAPTLMNA
SCHEMBL4475367 0.83 ADORA2A (0.39) ADORA2AADORA1NPC1PTGS2MAPT
SCHEMBL4491166 0.82 POLB (0.37) POLBNPSR1
SCHEMBL4478743 0.80 SLC2A1 (0.42) NPC1MAPTHPGDSMN1; SMN2KMT2A
SCHEMBL4482112 0.79 L3MBTL1 (0.39) PTGS2MAPTHPGDSMN1; SMN2KMT2A
SCHEMBL4490544 0.79 BRD4 (0.39) NPC1MAPTPIM1KMT2APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP claimed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP ADORA2A 868/4885ADORA1 319/4885TNKS 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.